NCI National Clinical Trials Network – Network Lead Academic Participating Site

NCI 国家临床试验网络 – 网络主导学术参与站点

• 批准号: 10357935
• 负责人: LAWRENCE E FLAHERTY
• 金额: $ 51.87万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10357935
• 关键词: Adult; Advisory Committees; Affect; American College of Radiology Imaging Network; Biological Markers; Cancer Center; Cancer Research Network; Clinical Research; Clinical Trials; Colon Carcinoma; Communities; Comprehensive Cancer Center; Data; Disease; Doctor of Medicine; Doctor of Philosophy; Eastern Cooperative Oncology Group; Enrollment; Evaluation; Faculty; Foundations; Funding; Goals; Grant; Healthcare Systems; Image; Institutes; Institution; Intervention; Intervention Trial; Lead; Leadership; Malignant Neoplasms; Manuscripts; Michigan; Minority; Minority Recruitment; Monitor; National Clinical Trials Network; Organ; Parents; Patient Care; Patient Education; Patients; Phase; Play; Population; Positioning Attribute; Principal Investigator; Protocols documentation; Publications; Qualifying; Research; Research Design; Role; Safety; Science; Site; Southwest Oncology Group; System; Translations; United States; Universities; Woman; base; clinical care; expectation; meetings; melanoma; member; mortality; multidisciplinary; novel therapeutics; personalized cancer therapy; programs

Wayne State University (WSU)/ Karmanos Cancer Institute (KCI) has been an active institutional member of the cooperative group system since 1972, an NCI designated Comprehensive Cancer Center since 1978, and a parent institution Phase I (U01) since 1993. We have an active membership in the NCTN and have been an active LAPS since its inception in 2013 enrolling patients in network trials through the CTSU and using the CIRB for activation. We have enrolled over 5,500 patients onto NCTN clinical trials over the past forty years and over 250 patients have been enrolled onto interventional trials since 2014, meeting and exceeding accrual goals in a consistent manner. Since April 2014, we have opened 52 NCTN trials, including 8 Alliance, 13 ECOG-ACRIN, 17 NRG and 14 SWOG. All adult NCTN qualifying Phase II and III protocols have been submitted through the CIRB for activation since 2009. Over the years, our faculty members have played an important role in both the administrative and scientific functions of the NCTN. Since 2014, eight faculty members have held nineteen leadership positions in SWOG and ECOG-ACRIN as well as serving on NCI organ site Task Forces and Steering Committees. Since 2014, 13 faculty members have been authors or co-authors of 41 NCTN abstracts or manuscripts, and 7 faculty members have been PI or Co-PIs of 11 NCTN clinical trials. Our Cancer Center is a unique urban based center of research, patient care and education which is reflected in our recruitment of minorities (24%) and women (44%) onto intervention trials. Since our inception, the cancer programs of WSU/KCI have been organized as multidisciplinary disease programs built on the premise that multidisciplinary clinical research and care provides the best treatment option for patients with cancer. Accordingly, the translation of ideas into Network Group proposals and studies and the incorporation of NCI designated high-priority trials into the WSU/KCI treatment priorities have been easily facilitated. NCI funded trials have the highest priority for activation within our institution. Dr. Lawrence Flaherty, a SWOG member since 1988, the SWOG U-10 PI since 1996 and LAPS PI since 2013 will serve as the PI of this submission. He was the SWOG Melanoma Vice Chair from 1990 until 2011 and has been Chair of the SWOG Data Safety and Monitoring Committee since 2011. Anthony Shields, M.D., PhD. is the Project Director/Principal Investigator of the WSU/KCI LAPS serves on the NCI Colon Cancer Task Force, the ECOG-ACRIN Principal Investigator Committee, the Scientific Planning Committee, and the Nomination Committee. He is the co-chair of the Experimental Imaging Sciences Committee and the Biomarker Steering Committee.

韦恩州立大学（WSU）/ Karmanos癌症研究所（KCI）一直是 自1972年以来的合作小组系统，自1978年以来的NCI指定的综合癌症中心，以及父母 第一阶段（U 01）自1993年以来。我们是NCTN的活跃成员，自2009年以来一直是LAPS的活跃成员。 其成立于2013年，通过CTSU招募患者参加网络试验，并使用CIRB进行激活。我们有 在过去的四十年里，NCTN临床试验招募了5,500多名患者， 自2014年以来，我们一直致力于干预性试验，以一致的方式达到并超过应计目标。自2014年4月以来，我们 目前已开展了52项NCTN试验，包括8项Alliance、13项ECOG-ACRIN、17项NRG和14项SWOG。所有成人NCTN资格 自2009年以来，已通过CIRB提交了第二阶段和第三阶段方案，以供启动。多年来，我们的教师 成员在NCTN的行政和科学职能方面发挥了重要作用。2014年以来，8 教师在SWOG和ECOG-ACRIN担任了19个领导职务，并在NCI机构任职 现场工作组和指导委员会。自2014年以来，13名教师是41名作者或共同作者 NCTN摘要或手稿，7名教员已成为11项NCTN临床试验的PI或Co-PI。我们的癌症 中心是一个独特的城市研究中心，病人护理和教育，这反映在我们的招聘， 少数民族（24%）和妇女（44%）参与干预试验。自成立以来，WSU/KCI的癌症项目 作为多学科疾病项目组织起来，其前提是多学科临床研究和护理 为癌症患者提供最佳治疗选择。相应地，翻译网群的思想也进入了 建议和研究，并将NCI指定的高优先级试验纳入WSU/KCI治疗优先事项 很容易就被促成了。NCI资助的试验在我们机构内具有最高的激活优先级。劳伦斯医生 Flaherty自1988年以来一直是SWOG成员，自1996年以来一直是SWOG U-10 PI，自2013年以来一直是LAPS PI。 这次提交。从1990年到2011年，他是SWOG黑色素瘤副主席，并一直担任SWOG数据主席 自2011年以来，安全和监测委员会。安东尼·希尔兹医学博士PhD.是项目总监/首席研究员， WSU/KCI LAPS服务于NCI结肠癌工作组，ECOG-ACRIN首席研究员委员会， 科学规划委员会和提名委员会。他是实验成像科学的联合主席 生物标志物指导委员会。